Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06270836 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Diabetic Retinopathy (DR)
A Phase 3 study of Diabetic Retinopathy, sponsored by Kodiak Sciences.
- Active
- Registry status
- Phase 3
- Development phase
- 255
- Enrollment target
- 20
- Study locations
NCT06270836: Active Phase 3 study of Diabetic Retinopathy, sponsored by Kodiak Sciences.
NCT06270836 is a Phase 3 study of Diabetic Retinopathy that is active but no longer recruiting, run by Kodiak Sciences. The registered enrollment target is 255 participants, below the 1,672-participant average among 57 other Diabetic Retinopathy trials with a reported enrollment target (85% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06270836, a Phase 3 study of Diabetic Retinopathy, is active but no longer recruiting, sponsored by Kodiak Sciences.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 255 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will demonstrate that tarcocimab 5 mg is superior to sham treatment in participants with DR.
Primary Outcome
Early Treatment Diabetic Retinopathy Diabetic Retinopathy Severity Scale (ETDRS DRSS), on a scale from 10 to 90, where lower scores represent better outcomes.
Conditions Studied
Interventions
- OTHER Sham injection
- DRUG Tarcocimab
Study Locations (20)
California
- Retina Consultants of Orange County - Fullerton
- Global Research Management, Inc. - Lugene Eye Institute - Glendale
- Retinal Consultants Medical Group, Inc. - Modesto
- Retina Consultants of Southern California - Redlands
- Retinal Consultants Medical Group, Inc. - Sacramento
North Carolina
- Asheville Eye Associates - Asheville
- North Carolina Retina Associates (Cary) - Cary
- North Carolina Retina Associates (Wake Forest) - Wake Forest
Florida
- Retina Group of Florida - Fort Lauderdale
- Center for Retina and Macular Disease - Winter Haven
Arizona
- Retina Associates SW - Tucson
Connecticut
- Retina Group of New England, PC - Waterford
Georgia
- Southeast Retina Center - Augusta
Illinois
- Springfield Clinic LLP - Springfield
Indiana
- Associated Vitreoretinal and Uveitis Consultants - Carmel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 255 participants |
| Start Date | 2024-05-01 |
| Est. Completion | 2026-01-31 |
| Phase | Phase 3 |
What the registry record for NCT06270836 still lists
NCT06270836 is an interventional study that assigns participants to a tested intervention. The registered 255 participants enrollment target is mid-sized for trials with a published cap, below the 1,672-participant average among 57 other Diabetic Retinopathy trials with a reported enrollment target (85% lower).
The record links to 1 condition, with Diabetic Retinopathy appearing as the primary indexed condition, and to 2 interventions - of which Sham injection is the first listed.
NCT06270836 names 20 study sites across 13 states, led by California, North Carolina, Florida.
Frequently Asked Questions
What is clinical trial NCT06270836 about?
NCT06270836 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Diabetic Retinopathy (DR)". This study will demonstrate that tarcocimab 5 mg is superior to sham treatment in participants with DR.
What is the current status of trial NCT06270836?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 255 participants. The study started on 2024-05-01. Estimated completion is 2026-01-31.
What conditions does trial NCT06270836 study?
This clinical trial studies the following conditions: Diabetic Retinopathy.
What interventions are being tested in trial NCT06270836?
The interventions under investigation include: Sham injection (OTHER), Tarcocimab (DRUG).
Who is sponsoring clinical trial NCT06270836?
This trial is sponsored by Kodiak Sciences, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06270836 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Retinopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06270836's enrollment target sits among peer trials
255 26th of 57 higher than 32 of 57 other Diabetic Retinopathy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetic Retinopathy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Fenofibrate for Prevention of DR Worsening
RECRUITING · Phase 3
-
A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm
ACTIVE NOT RECRUITING · Phase 3
-
Safety and Efficacy Study of Vitrase for Clearance of Severe Vitreous Hemorrhage
COMPLETED · Phase 3
-
Octreotide Acetate in Microspheres in Patients With Diabetic Retinopathy
COMPLETED · Phase 3
-
Reduction in the Occurrence of Center-Involved Diabetic Macular Edema
COMPLETED · Phase 3
-
Anti-VEGF Treatment for Prevention of PDR/DME
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04623424 · 255 participants
Intestinal Microbiota in Stem Cell Transplant Transplant Admission
- NCT05114798 · 255 participants · NA
Time-restricted Eating Versus Daily Continuous Calorie Restriction on Body Weight and Colorectal Cancer Risk Markers
- NCT05336188 · 255 participants · Phase 2
Neurocognitive Mechanisms Underlying Smartphone-Assisted Prevention of Relapse in Opioid Use Disorder
- NCT05486637 · 255 participants · Early Phase 1
Vocal Emotion Communication With Cochlear Implants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI